Log In
Print
BCIQ
Print
Print this Print this
 

Xalkori, crizotinib (PF-02341066)

Also known as: PF-2341066

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionDual inhibitor of c-Met receptor tyrosine kinase and anaplastic lymphoma kinase (ALK) and their oncogenic variants
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) ; Anaplastic lymphoma kinase (ALK)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor; c-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$2,850.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today